Cardiovascular disease (CVD) is a
leading cause of death in the United States. Over 71
million Americans currently suffer from some form of
heart disease, and one million people die every year
despite access to an extensive array of modern drugs
and surgical procedures. The situation in developing
countries is much worse, as the high expense of advanced
Western medical options severely restricts patient
access to many contemporary treatments.
CardioPhase is a Chinese medicinal
formula based on traditional theories about restoration
and improvement of heart function. Developed over a
ten-year period by a team of leading medical researchers
at China’s National Institute of Science, CardioPhase has been shown to alleviate myocardial damage induced
by anoxia (lack of oxygen) and ischemia (lack of blood
flow) to heart tissues.
In addition to nourishing heart tissues
and enhancing hemodynamics (literally “blood
dynamics”) CardioPhase has been shown to improve
the physical characteristics of blood cells while supporting
blood flow to the heart. CardioPhase has also been
shown to be safe for regular use, exhibiting virtually
no toxic effects in large and extended doses.
Heart
Disease Taking Toll
The lack of affordable treatments
for heart disease posed serious problems for China
in the early 1980s. The country was in the midst of
an intense period of modernization as millions of rural
workers abandoned their traditional farms to work in
newly built factories and industrial parks. An unintended
consequence of this unprecedented migration was that,
as workers left behind their traditional life-styles,
they also gave up their traditional foods and adopted
a Westernized diet high in calories, saturated fats
and processed sugars. Not surprisingly the outcome
of this shift in dietary habits was a sudden surge
in the incidence of heart disease, and by 1989 a staggering
12 million people were dying from heart disease every
year.
To cope with the crisis, in 1989
Chinese health authorities drafted a team of leading
scientists from the prestigious National Academy of
Science in Beijing and commissioned them to develop
a natural, inexpensive and non-intrusive solution for
heart disease. After a decade of intense research,
the team introduced CardioPhase, a unique herbal formula
based on traditional Chinese theories of restoration
and improvement of heart function. After passing a
series of stringent animal and human trials, CardioPhase was certified by the Academy of Sciences in 1999 for
use in hospitals as a primary treatment for a variety
of cardiac disorders, including chronic congestive
heart failure.
Following its approval, ongoing clinical
trials across China continued to demonstrate statistically
significant results with CardioPhase. In particular,
the formula was found to alleviate myocardial damage
induced by anoxia (lack of oxygen) and ischemia (lack
of blood flow) to heart tissues by lowering rates of
lipid peroxidation and increasing endogenous levels
of sodium oxide dismutase (SOD).
CardioPhase was also found to reduce
pulmonary arterial blood pressure, improve microcirculation,
enhance cardiac output and reduce clinical symptoms
such as high blood pressure, shortness of breath, angina,
palpitations and dizziness.
Research Studies
1.
Phase 2 Clinical Trial on 304 Cases of Myocardial
Damage
Researchers treated 304 patients previously diagnosed
with myocardial damage and cardiac insufficiency. After
receiving CardioPhase for a period of six weeks, 100
patients (30%) were shown to be free of previous clinical
symptoms, including angina, arrhythmia, dizziness and
shortness of breath. The study authors noted that electrocardiogram
(ECG or EKG) scores for this group had returned to
normal (healthy) values.
An additional 189 subjects from the
same study (62%) showed signs of significant benefits,
including improvements in one or more symptoms and/or
significant improvements in ECG/EKG scores. Of the
total of 304 subjects receiving CardioPhase, only 15
patients (less than 4%) failed to show signs of improvement.
Put in perspective, 95% of all participants experienced
significant improvement after only six weeks of treatment.
In summarizing their findings the
study authors noted that CardioPhase’s ability
to enhance blood SOD activity and reduce plasma LPO
concentrations made it “an effective agent for
improving and restoring myocardial functions.” Noting
CardioPhase’s ability to reduce pulmonary arterial
pressure and pulmonary capillary wedge pressure, the
researchers concluded that “CardioPhase can be
safely used for myocardial damage caused by various
organic cardiopathies.”
2.
Clinical Treatment of 52 Cases of Myocardial Ischemia
Myocardial ischemia occurs when blood flow to heart
tissues is impaired, reducing the supply of oxygen
and damaging heart tissues. The condition is usually
caused by coronary artery disease.
Animal experiments had previously
shown that CardioPhase improves cases of myocardial
ischemia by restoring myocardial microcirculation,
enhancing myocardial metabolism, raising serum levels
of glutathione, and stimulating oxidation-reduction
to reduce free radical damage to protect heart tissues
and promote resistance to damage.
In
this study CardioPhase was found to improve clinical
symptoms in 87% of the patients and improve electrocardiogram
scores in 42% the patients (Table 1). By comparison,
68% of patients in a control group receiving propranolol,
a non-selective beta blocker, showed signs of improvement,
including 40% improvement in ECG/EKG scores.
CardioPhase
Treatment Group
|
Dizziness
|
Palpitations
|
Shortness of Breath
|
Chest Distress
|
Angina
|
Debility
|
Totals
|
Pre-treatment (n)
|
15
|
38
|
23
|
40
|
18
|
13
|
147
|
Effective (n)
|
15
|
32
|
18
|
38
|
14
|
11
|
128
|
No Change (n)
|
0
|
6
|
5
|
2
|
2
|
2
|
19
|
Table
1. Alleviation of symptoms in 52 cases
of myocardial ischemia treated with CardioPhase.
|
The
study authors report that these findings indicate
that CardioPhase is an effective treatment for myocardial
ischemia and is superior to propranolol, as demonstrated
by the clearance of symptoms and improved
EKG scores.
CardioPhase was found to benefit myocardial ischemia
and myocardial damage from many types of heart disease,
including myocarditis and coronary artery disease.
In addition to being superior to propranolol for
relieving clinical symptoms and improving ECG/EKG readings,
CardioPhase was also determined be free of side effects
3.
Hemodynamic Effects in Patients with Congestive
Heart Failure
Researchers measured the hemodynamic effects of CardioPhase on 32 patients diagnosed with congestive heart failure
(CHF). Baseline readings of heart rate, blood pressure,
mean right atrial pressure (MRAP), mean pulmonary arterial
pressure (MPAP), pulmonary wedge pressure (PWP) and
cardiac index (CI) readings were measured at the start
of the study and again every hour for eight hours following
treatment with CardioPhase.
The study revealed that CardioPhase reduced mean right atrial pressure (MRAP) and pulmonary
wedge pressure (PWP), and improved the cardiac index
(CI) (P<0.05) for a period of 4 hours after intake.
4.
Improved Plasma Viscosity in 105 Patients with
Coronary Artery Disease
Researchers measured CardioPhase’s therapeutic
effect on plasma viscosity levels in 105 patients diagnosed
with coronary artery disease. After 40 days of treatment
with CardioPhase all patients showed statistically
significant decreases in plasma viscosity. Importantly,
the subgroup of patients with elevated blood viscosity
also showed statistically significant decreases in
plasma viscosity. The study authors concluded that “our
results indicate that administration of CardioPhase can decrease plasma viscosity and reduce the impact
of this contributing factor on the progression of coronary
heart disease and eventual heart infarction.”
5.
Clinical Effects on 119 Cases Of Myocardial Damage
Researchers from the Cardiac Medicine Department
of First Medical College, Xi’an, conducted a clinical
trial on 119 patients diagnosed with coronary artery
disease and myocardial damage caused by other organic
heart disease. The subjects, 65 males and 54 females,
received CardioPhase three times daily for a period
of six weeks. The study outcome showed that CardioPhase improved blood supply and oxygen delivery to heart
tissues, thereby reducing symptoms such as angina and
shortness of breath while improving electrocardiograms
(i.e., improved S-T segment depression, T wave flatness
and inversion).
6.
Treatment of 54 Patients with Myocardial Damage
Researchers at Tianjin University of Traditional
Chinese Medicine treated 54 patients hospitalized with myocardial
damage caused by coronary artery disease. Patients
were treated with CardioPhase for a period of six weeks.
At the conclusion of the trial 22 subjects were diagnosed
as recovered (i.e. clinical symptoms fully resolved
and electrocardiogram S-T segments and T waves returned
to normal). An additional 27 cases were deemed effective
(i.e. symptoms were partially improved, accompanied
by improvement or normalization of S-T segments and/or
T waves). The total effective power for subjects receiving
CardioPhase was 90%. Clinical measurements also revealed
that CardioPhase increased SOD activity in red cells
reduced LPO in plasma, and normalized blood pressure
levels.
Summary
The study authors report that their findings indicate
that CardioPhase is an effective treatment for myocardial
ischemia and is superior to propranolol, as demonstrated
by the clearance of symptoms and improved EKG scores.
CardioPhase was found to benefit myocardial ischemia
and myocardial damage from many types of heart disease,
including myocarditis and coronary artery disease.
In addition to being superior to propranolol for
relieving clinical symptoms and improving ECG/ EKG
readings, CardioPhase was also determined to be free
of side effects.
Directions
As a dietary supplement take 2 capsules, 3 times daily
for optimal cardiovascular support. For increased
restorative effect intake may be increased to 4 capsules,
3 times daily.
